Nanomaterial‐Mediated Delivery of MLKL Plasmids Sensitizes Tumors to Immunotherapy and Reduces Metastases
Tianjiao Chu,Christy Maksoudian,Stefania Pedrotti,Mukaddes Izci,Irati Perez Gilabert,Xanthippi Koutsoumpou,Ara Sargsian,Hermon Girmatsion,Filipa Roque Goncalves,Colinda LGJ Scheele,Bella B. Manshian,Stefaan J. Soenen
DOI: https://doi.org/10.1002/adhm.202401306
IF: 10
2024-07-21
Advanced Healthcare Materials
Abstract:Cancer immunotherapy induces antitumor responses but struggles with solid tumors due to an immunosuppressive microenvironment. Here, a HPAEs nanoparticle system is developed to deliver MLKL plasmid DNA, enhancing immune antigen presentation, antitumor response, and survival in mice. Combined with anti‐PD1 immunotherapy, this strategy makes it possible to treat tumors that do not respond to immunotherapy on its own. Cancer immunotherapy has emerged as a promising approach for the induction of an antitumor response. While immunotherapy response rates are very high in some cancers, the efficacy against solid tumors remains limited caused by the presence of an immunosuppressive tumor microenvironment. Induction of immunogenic cell death (ICD) in the tumor can be used to boost immunotherapy response in solid cancers by eliciting the release of immune‐stimulatory components. However, the delivery of components inducing ICD to tumor sites remains a challenge. Here, a novel delivery method is described for antitumor therapy based on MLKL (Mixed Lineage Kinase Domain‐Like), a key mediator of necroptosis and inducer of ICD. A novel highly branched poly (β‐amino ester)s (HPAEs) system is designed to efficiently deliver MLKL plasmid DNA to the tumor with consequent enhancement of immune antigen presentation for T cell responses in vitro, and improved antitumor response and prolonged survival in tumor‐bearing mice. Combination of the therapy with anti‐PD‐1 treatment revealed significant changes in the composition of the tumor microenvironment, including increased infiltration of CD8+ T cells and tumor‐associated lymphocytes. Overall, the HPAEs delivery system can enhance MLKL‐based cancer immunotherapy and promote antitumor immune responses, providing a potential treatment to boost cancer immunotherapies.
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials